Halozyme Therapeutics, Inc. (HALO)

Market Cap	8.07B +1.6%
Revenue (ttm)	1.40B +37.6%
Net Income	316.89M -28.6%
EPS	2.56 -25.4%
Shares Out	118.47M
PE Ratio	26.58
Forward PE	8.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	463,749
Open	66.82
Previous Close	66.98
Day's Range	66.54 - 68.31
52-Week Range	47.50 - 82.22
Beta	1.03
Analysts	Buy
Price Target	78.18 (+14.8%)
Earnings Date	May 5, 2026

About HALO

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 423
• Stock Exchange: NASDAQ
• Ticker Symbol: HALO
• Website: https://halozyme.com

Financial Performance

In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.

Analyst Summary

According to 11 analysts, the average rating for HALO stock is "Buy." The 12-month stock price target is $78.18, which is an increase of 14.80% from the latest price.

Price Target

$78.18

(14.80% upside)

Analyst Consensus: Buy